# Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia

> **NCT01259713** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 355 (actual)

## Conditions studied

- Invasive Fungal Disease

## Interventions

- **DRUG:** Liposomal amphotericin B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01259713
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2015-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259713, "Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01259713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*